

PTO/SB/08A (08-00)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
to a collection of information unless it displays a valid OMB control number.

to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

<b>Application Number</b>	09/874,117
<b>Filing Date</b>	6/4/01
<b>First Named Inventor</b>	Carol Wright
<b>Group Art Unit</b>	3738
<b>Examiner Name</b>	S. J. Jackson
<b>Attorney Docket Number</b>	JJI-51

Filing Date	6/4/01
-------------	--------

First Named Inventor	Carol Wright
----------------------	--------------

Group Art Unit	3738
----------------	------

Examiner Name	S. J. Jackson
---------------	---------------

Attorney Docket Number	JJI-51
------------------------	--------

## U.S. PATENT DOCUMENTS

[illegible]

U.S. Patent Document	
Number	Kind Code <sup>2</sup> (if known)

Name of Patentee or Applicant  
of Cited Document

Date of Publication  
of Cited Document  
mm-dd-yyyy

Pages, Columns, Lines,  
where relevant passages  
or relevant figures appear

## FOREIGN PATENT DOCUMENTS

[illegible]

Foreign Patent Document		
Office <sup>3</sup>	Number <sup>4</sup>	KindCode <sup>6</sup>

Name of Patentee or  
Applicant of Cited Document

Date of Publication  
of Cited Document  
mm-dd-yyyy

where relevant  
passages or relevant  
figures appear

T

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

FAXED COPY RECEIVED

JAN 10 2003

TECHNOLOGY CENTER 3700

Under the Patent Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 3

 PTO/SB/08A (08-00)  
 Approved for use through 10/31/2002. OMB 0651-0031  
 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Application Number	09/874,117
Filing Date	June 4, 2001
First Named Inventor	Carol Wright
Group Art Unit	3738
Examiner Name	S. J. Jackson
Attorney Docket Number	JJI-51

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
S.J.	1	MARX, STEVEN O. et al., Rapamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle Cells, Circulation Research, 1995;76(3):412-417	/
	2	SERRUYS, PATRICK W. et al., Heparin-Coated Palmaz-Schatz Stents in Human Coronary Arteries, Circulation, 1996;93:412-422	
	3	LUNDERGAN, CONOR F., MD et al., Peptide Inhibition of Myointimal Proliferation by Angiotensin, a Somatostatin Analogue, JACC Vol. 17, No. 6, May 1991:132B-6B	
	4	LIU, MING WEI, MD et al., Restenosis After Coronary Angioplasty: Potential Biologic Determinants and Role of Intimal Hyperplasia, Circulation 1989, 79:1374-1387.	
	5	SERRUYS, P. W. et al., Evaluation of Ketanserin in the Prevention of Restenosis After Percutaneous Transluminal Coronary Angioplasty - A Multicenter Randomized Double-Blind Placebo-Controlled Trial, Circulation Vol 88, No 4, Part 1, Oct 1993, 1588-1601	
	6	BERK, BRADFORD C. MD et al., Pharmacologic Roles of Heparin and Glucocorticoids to Prevent Restenosis After Coronary Angioplasty, JACC Vol. 17, No. 6, May 1991:111B-7B	
	7	SERRUYS, PATRICK W. MD et al., A Comparison of Balloon-Expandable Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery Disease, The New England Journal of Medicine, Vol 331, No. 8, August 25, 1994, 489-495	
	8	FISCHMAN, DAVID L. MD et al., A Randomized Comparison of Coronary Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease, The New England Journal of Medicine, Vol 331, No. 8, August 25, 1994, 496-501	
	9	COLBURN, MICHAEL D. MD et al., Dose Responsive suppression of myointimal hyperplasia by dexamethasone, Journal of Vascular Surgery, Vol 15, No 3, March 1992, 510-518	
	10	LIU, MING, W. MD, Trapidil in Preventing Restenosis After Balloon Angioplasty in the Atherosclerotic Rabbit, Circulation, Vol 81, No 3, March 1990, 1089-1093	
	11	HANSSON, GÖRAN K. MD, et al., Interferon- $\gamma$ Inhibits Arterial Stenosis After Injury, Circulation, Vol 84, No 3, Sept 1991, 1288-1292	
	12	SNOW, ALAN D. et al., Heparin Modulates the Composition of the Extracellular Matrix Domain Surrounding Arterial Smooth Muscle Cells, American Journal of Pathology, Vol 137, No. 2, August 1990, 313-330	
	13	POPMA, JEFFREY J. MD et al., Clinical Trials of Restenosis After Coronary Angioplasty, Circulation Vol 84, No 3, Sept 1991, 1428-1438	
	14	CAMPBELL, GORDON R. et al., Phenotypic Modulation of Smooth Muscle Cells in Primary Culture, Vascular Smooth Muscle Cells in Culture, CRC Press 1987, pp39-55	
	15	CLOWES, ALEXANDER W. et al., Significance of Quiescent Smooth Muscle Migration in the Injured Rat Carotid Artery, Cir Res 58: 139-145, 1985	
	16	LANGE, RICHARD A. MD et al., Restenosis After Coronary Balloon Angioplasty, Annu. Rev. Med. 1991, 42:127-32	
	17	FRANKLIN, STEPHEN, M. MD et al., Pharmacologic prevention of restenosis after coronary angioplasty: review of the randomized clinical trials, Coronary Artery Disease, March 1993, Vol 4, No 3, 232-242	
	18	Suppression by heparin of smooth muscle cell proliferation in injured arteries, Nature, Vol 265, Feb 17, 1977, 625-626	
	19	GUYTON, JOHN, R. et al., Inhibition of Rat Arterial Smooth Muscle Cell Proliferation by Heparin, Circulation Research, Vol 46, No 5, May 1980, 825-834	
	20	CLOWES, ALEXANDER W. et al., Kinetics of Cellular Proliferation after Arterial Injury, Circulation Research, Vol 58, No 6, June 1986, 839-845	
	21	MAJESKY, MARK W., et al., Heparin Regulates Smooth Muscle S Phase Entry in the Injured Rat Carotid Artery, Circulation Research, Vol 61, No 2, August 1987, 296-300	
	22	OKADA, TOMOHIRO, MD et al., Localized Release of Perivascular Heparin Inhibits Intimal Proliferation after Endothelial Injury without Systemic Anticoagulation, Neurosurgery, Vol 25, No 6, 1989, 892-898	
	23	VASEY, CHARLES G. et al., Clinical Cardiology: Stress Echo and Coronary Flow, Supplement II Circulation, Vol 80, No 4, October 1989, II-66	
	24	POWELL, JERRY S. et al., Inhibitors of Angiotensin-Converting Enzyme Prevent Myointimal Proliferation After Vascular Injury, Science, Vol 245, July 14, 1989, 186-188	
	25	JONASSON, LENA et al., Cyclosporin A Inhibits smooth muscle proliferation in the vascular response to injury, Proc. Natl. Acad. Sci USA 85 (1988), pp 2303-2308	
	26	NEMECEK, GEORGINA M. et al., Terbutaline Inhibits the Mitogenic Response to Platelet-Derived Growth Factor in Vitro and Neointimal Proliferation in Vivo, The Journal of Pharmacology and Experimental Therapeutics, Vol 248, No 3, 1988, 1187-1194	
	27	SIEKIERKA, JOHN J., Probing T-Cell Signal Transduction Pathways with the Immunosuppressive Drugs, FK-506 and Rapamycin, Immunologic Research 1994, 13: 110-116	

Examiner Signature	Date Considered
<i>S. J. Jackson</i>	1 / 13 / 03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

<b>Application Number</b>	09/874,117
<b>Filing Date</b>	June 4, 2001
<b>First Named Inventor</b>	Carol Wright
<b>Group Art Unit</b>	3738
<b>Examiner Name</b>	S. J. Jackson
<b>Attorney Docket Number</b>	JJI-51

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner Signature	<i>S. Jack</i>	Date Considered	11/13/03
-----------------------	----------------	--------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.